Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Horizon Therapeutics (HZNP)

Horizon Therapeutics (HZNP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,498,292
  • Shares Outstanding, K 224,074
  • Annual Sales, $ 2,200 M
  • Annual Income, $ 389,800 K
  • 60-Month Beta 1.14
  • Price/Sales 9.27
  • Price/Cash Flow 17.47
  • Price/Book 4.99
Trade HZNP with:

Options Overview

Details
  • Implied Volatility 50.80%
  • Historical Volatility 52.23%
  • IV Percentile 32%
  • IV Rank 30.53%
  • IV High 69.87% on 04/13/20
  • IV Low 42.42% on 08/13/20
  • Put/Call Vol Ratio 0.59
  • Today's Volume 722
  • Volume Avg (30-Day) 1,646
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 46,763
  • Open Int (30-Day) 46,150

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 0.19
  • Number of Estimates 6
  • High Estimate 0.37
  • Low Estimate -0.01
  • Prior Year 0.44
  • Growth Rate Est. (year over year) -56.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
79.81 +12.51%
on 03/29/21
93.73 -4.20%
on 04/01/21
-1.99 (-2.17%)
since 03/12/21
3-Month
70.15 +28.00%
on 01/27/21
96.54 -6.99%
on 02/24/21
+11.06 (+14.05%)
since 01/12/21
52-Week
30.00 +199.30%
on 04/13/20
96.54 -6.99%
on 02/24/21
+58.76 (+189.37%)
since 04/09/20

Most Recent Stories

More News
Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For(R)

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has been named one of Fortune's 100 Best Companies to Work For(R) in the United States. This is Horizon's first time being included on the...

HZNP : 89.79 (-1.85%)
Horizon Therapeutics plc to Release First-Quarter 2021 Financial Results and Host Webcast on May 5, 2021

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its first-quarter 2021 financial results will be released on Wednesday, May 5, 2021. Following the announcement, Horizon's management will host...

HZNP : 89.79 (-1.85%)
RECIPE Randomized Controlled Trial Data Published in Arthritis & Rheumatology Show Higher Response Rates Using KRYSTEXXA(R) (pegloticase injection) with the Immunomodulator Mycophenolate Mofetil

Horizon Therapeutics plc (Nasdaq: HZNP) announced the publication of data from the first randomized controlled clinical trial (RCT) of KRYSTEXXA (pegloticase injection) concomitantly used with an immunomodulator,...

HZNP : 89.79 (-1.85%)
New UPLIZNA(R) (inebilizumab-cdon) Data in People With Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the American Academy of Neurology's 73rd Annual Meeting

-- New survey results demonstrate NMOSD patient attitudes towards diagnosis and treatment --

HZNP : 89.79 (-1.85%)
Horizon Therapeutics plc to Resupply Market With TEPEZZA(R) (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED) Beginning in April

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has approved a prior approval supplement (PAS) to the previously approved Biologics Licensing Application...

HZNP : 89.79 (-1.85%)
Horizon Therapeutics and Chicago Cubs Announce Legacy Partnership

Horizon Therapeutics (Nasdaq: HZNP) and the Cubs today announced a Legacy Partnership that includes a Cubs STEAM Program, presented by Horizon, which will include an innovative, citywide science camp and...

HZNP : 89.79 (-1.85%)
Why Is Horizon Therapeutics (HZNP) Down 8.1% Since Last Earnings Report?

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HZNP : 89.79 (-1.85%)
First Patient Enrolls in FORWARD Trial to Evaluate Monthly Dosing of KRYSTEXXA(R) (pegloticase injection) and Methotrexate to Treat Uncontrolled Gout

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a clinical trial that will evaluate a monthly dosing regimen of 16 mg of KRYSTEXXA (pegloticase injection) concomitantly...

HZNP : 89.79 (-1.85%)
UPLIZNA(R) (inebilizumab-cdon) Approved by Japanese Ministry of Health, Labour and Welfare for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its strategic partner Mitsubishi Tanabe Pharma Corporation (MTPC) has received manufacturing and marketing approval of UPLIZNA for the prevention...

MTZPY : 18.6000 (-0.13%)
HZNP : 89.79 (-1.85%)
Horizon Therapeutics plc Launches The Horizon Prize with Massachusetts Institute of Technology (MIT) Solve to Advance Solutions for the Rare Disease Community

Horizon Therapeutics plc (Nasdaq: HZNP), in partnership with MIT Solve, a marketplace for social impact innovation, today announced it has created a first-of-its-kind annual global innovation challenge...

HZNP : 89.79 (-1.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Horizon Therapeutics PLC is a biopharmaceutical company. It is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines which address unmet medical needs. The Company markets medicines through its orphan, rheumatology and primary care business units. ...

See More

Key Turning Points

3rd Resistance Point 94.37
2nd Resistance Point 92.75
1st Resistance Point 91.27
Last Price 89.79
1st Support Level 88.17
2nd Support Level 86.55
3rd Support Level 85.07

See More

52-Week High 96.54
Last Price 89.79
Fibonacci 61.8% 71.12
Fibonacci 50% 63.27
Fibonacci 38.2% 55.42
52-Week Low 30.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar